

Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults

Authors: Tianyu Sun¹, Linwei Li¹, Katherine Mues², Mihaela Georgieva¹, Brenna Kirk², James Mansi¹, Nicolas Van de Velde¹, Ekkehard Beck¹

Affiliations: ¹Moderna, Inc., Cambridge, MA, USA; ²Aetion, Inc., New York, NY, USA

Corresponding author:

Tianyu Sun, PhD.

Moderna, Inc, 325 Binney Street, Cambridge, MA 02142, USA.

Email: Tianyu.Sun@modernatx.com

SUPPLEMENTARY MATERIAL

Supplemental Table 1. Codes to identify mRNA-1273 and BNT162b vaccines

mRNA-1273 primary series vaccine	mRNA-1273 booster vaccine	BNT162b2 primary series vaccine	BNT162b2 booster vaccine
CPT	CPT	CPT	CPT
0011A	91306	91300	0004A
0012A	0064A	0001A	0054A
91301	0094A	0002A	91312
National Drug Code	91309	91305	0124A
80777027310	91313	0051A	0003A
80777027315	0134A	0052A	0053A
80777027398	0013A	National Drug Code	National Drug Code
80777027399	National Drug Code	59267100001	59267030401
8077727315	8077727505	59267100002	5926703041
8077727398	80777027505	59267100003	5926703042
8077727399	8077728205	5926710001	59267030402
8077727310	80777028205	5926710002	59267140401
8077710011	8077728299	5926710003	5926714041
8077701001	80777028005	59267102501	5926714042
8077710099	80777028099	5926710251	59267140402
80777010011	80777028299	00069202501	
80777010099	80777027599	0006920251	
	8077727599	00069202510	
		0069202501	
		0069202510	
		0069202525	

		00069202525	
		5926710252	
		59267102502	
		5926710253	
		59267102503	
		5926710254	
		59267102504	

CPT, Current Procedural Terminology.

Supplemental Table 2. Diagnosis codes used to identify respiratory distress

Conditions	ICD-10 codes used
Coronavirus related diseases*	B97.29 - Other coronavirus as the cause of diseases classified elsewhere
	J12.89 - Other viral pneumonia
	J20.8 - Acute bronchitis due to other specified organisms
	J22 - Unspecified acute lower respiratory infection
	J40 - Bronchitis, not specified as acute or chronic
	J80 - Acute respiratory distress syndrome
	J98.8 - Other specified respiratory disorders
Pneumonia due to coronavirus*	J12.81 - Pneumonia due to SARS-associated coronavirus
	J12.82 - Pneumonia due to SARS-associated coronavirus 2019
	B34.2 - Coronavirus infection, unspecified
	B97.29 - Other coronavirus as the cause of diseases classified elsewhere
	B97.21 - SARS-associated coronavirus as the cause of diseases classified elsewhere
Acute respiratory distress syndrome*	J80 - Acute respiratory distress syndrome
Other ARDS related pneumonia*	J12 - Viral pneumonia, not elsewhere classified
	J12.81 - Pneumonia due to SARS-associated coronavirus
	J12.89 - Other viral pneumonia
	J12.9 - Viral pneumonia, unspecified
	J13 - Pneumonia due to Streptococcus pneumoniae

	J14 - Pneumonia due to Hemophilus influenzae
	J15 - Bacterial pneumonia, not elsewhere classified
	J15.0 - Pneumonia due to Klebsiella pneumoniae
	J15.1 - Pneumonia due to Pseudomonas
	J15.20 - Pneumonia due to staphylococcus, unspecified
	J15.211 - Pneumonia due to Methicillin susceptible Staphylococcus aureus
	J15.212 - Pneumonia due to Methicillin resistant Staphylococcus aureus
	J15.29 - Pneumonia due to other staphylococcus
	J15.3 - Pneumonia due to streptococcus, group B
	J15.4 - Pneumonia due to other streptococci
	J15.5 - Pneumonia due to Escherichia coli
	J15.6 - Pneumonia due to other Gram-negative bacteria
	J15.7 - Pneumonia due to Mycoplasma pneumoniae
	J15.8 - Pneumonia due to other specified bacteria
	J15.9 - Unspecified bacterial pneumonia
	J16 - Pneumonia due to other infectious organisms, not elsewhere classified
	J16.8 - Pneumonia due to other specified infectious organisms
	J17 - Pneumonia in diseases classified elsewhere
	J18.0 - Bronchopneumonia, unspecified organism

	J18.1 - Lobar pneumonia, unspecified organism
	J18.8 - Other pneumonia, unspecified organism
	J18.9 - Pneumonia, unspecified organism
	J95.851 - Ventilator associated pneumonia
Other ARDS related Sepsis*	A02.1 - Salmonella sepsis
	A20.7 - Septicemic plague
	A22.7 - Anthrax sepsis
	A26.7 - Erysipelothrix sepsis
	A32.7 - Listerial sepsis
	A40 - Streptococcal sepsis
	A40.0 - Sepsis due to streptococcus, group A
	A40.1 - Sepsis due to streptococcus, group B
	A40.3 - Sepsis due to Streptococcus pneumoniae
	A40.8 - Other streptococcal sepsis
	A40.9 - Streptococcal sepsis, unspecified
	A41 - Other sepsis
	A41.0 - Sepsis due to Staphylococcus aureus
	A41.01 - Sepsis due to Methicillin susceptible Staphylococcus aureus
	A41.02 - Sepsis due to Methicillin resistant Staphylococcus aureus

	A41.1 - Sepsis due to other specified staphylococcus
	A41.2 - Sepsis due to unspecified staphylococcus
	A41.3 - Sepsis due to Hemophilus influenzae
	A41.4 - Sepsis due to anaerobes
	A41.5 - Sepsis due to other Gram-negative organisms
	A41.50 - Gram-negative sepsis, unspecified
	A41.51 - Sepsis due to Escherichia coli [E. coli]
	A41.52 - Sepsis due to Pseudomonas
	A41.53 - Sepsis due to Serratia
	A41.59 - Other Gram-negative sepsis
	A41.8 - Other specified sepsis
	A41.81 - Sepsis due to Enterococcus
	A41.89 - Other specified sepsis
	A41.9 - Sepsis, unspecified organism
	A42.7 - Actinomycotic sepsis
	A54.86 - Gonococcal sepsis
	B37.7 - Candidal sepsis
	I26.01 - Septic pulmonary embolism with acute cor pulmonale
	I26.90 - Septic pulmonary embolism without acute cor pulmonale

	I76 - Septic arterial embolism
	P36 - Bacterial sepsis of newborn
	P36.0 - Sepsis of newborn due to streptococcus, group B
	P36.1 - Sepsis of newborn due to other and unspecified streptococci
	P36.10 - Sepsis of newborn due to unspecified streptococci
	P36.19 - Sepsis of newborn due to other streptococci
	P36.2 - Sepsis of newborn due to Staphylococcus aureus
	P36.3 - Sepsis of newborn due to other and unspecified staphylococci
	P36.30 - Sepsis of newborn due to unspecified staphylococci
	P36.39 - Sepsis of newborn due to other staphylococci
	P36.4 - Sepsis of newborn due to Escherichia coli
	P36.5 - Sepsis of newborn due to anaerobes
	P36.8 - Other bacterial sepsis of newborn
	P36.9 - Bacterial sepsis of newborn, unspecified
	R65.2 - Severe sepsis
	R65.20 - Severe sepsis without septic shock
	R65.21 - Severe sepsis with septic shock
	T81.12 - Postprocedural septic shock
	T81.12XA - Postprocedural septic shock, initial encounter

	T81.12XD - Postprocedural septic shock, subsequent encounter
	T81.12XS - Postprocedural septic shock, sequela
	T81.44 - Sepsis following a procedure
	T81.44XA - Sepsis following a procedure, initial encounter
	T81.44XD - Sepsis following a procedure, subsequent encounter
	T81.44XS - Sepsis following a procedure, sequela
Bronchitis*	J20.8 - Acute bronchitis due to other specified organisms
	J40 - Bronchitis, not specified as acute or chronic
Respiratory infection*	J22 - Unspecified acute lower respiratory infection
	J98.8 - Other specified respiratory disorders
Cough	R05 - Cough
Shortness of breath	R06.2 - Wheezing
Intubation diagnosis	T88.4 - Failed or difficult intubation
	T88.4XXA - Failed or difficult intubation, initial encounter
	T88.4XXD - Failed or difficult intubation, subsequent encounter
	T88.4XXS - Failed or difficult intubation, sequela
Ventilation related diagnosis	J95.85 - Complication of respirator [ventilator]
	J95.851 - Ventilator associated pneumonia
	J95.859 - Other complication of respirator [ventilator]

	Z99.11 - Dependence on respirator [ventilator] status
Hypoxia and supplemental oxygen	J96.01 - Acute respiratory failure with hypoxia
	J96.11 - Chronic respiratory failure with hypoxia
	J96.21 - Acute and chronic respiratory failure with hypoxia
	J96.91 - Respiratory failure, unspecified with hypoxia
	Z99.81 - Dependence on supplemental oxygen
	R09.0 - Asphyxia and hypoxemia
	R09.01 - Asphyxia
	R09.02 - Hypoxemia
*Included in the more restricted respiratory distress	

ARDS, acute respiratory distress syndrome; E. coli; *Escherichia coli*.

Supplemental Table 3. Calendar Month/Year of Entry Date of IC adults with a third dose regimen of BNT162b2 or mRNA-1273

	BNT162b2	mRNA-1273	ASD before weighting	ASD after weighting
Number of patients	60084	52943		
Month/Year of Entry Date; n (%)				
February 2021	1 (0.0%)	0 (0.0%)	0.006	0.000
March 2021	20 (0.0%)	14 (0.0%)	0.004	0.000
April 2021	60 (0.1%)	54 (0.1%)	0.001	0.000
May 2021	57 (0.1%)	61 (0.1%)	0.006	0.000
June 2021	70 (0.1%)	52 (0.1%)	0.006	0.000
July 2021	110 (0.2%)	52 (0.1%)	0.023	0.000
August 2021	5,377 (8.9%)	4,832 (9.1%)	0.006	0.000
September 2021	5,464 (9.1%)	3,451 (6.5%)	0.096	0.000
October 2021	9,529 (15.9%)	4,848 (9.2%)	0.204	0.000
November 2021	10,010 (16.7%)	12,386 (23.4%)	0.169	0.000
December 2021	11,582 (19.3%)	11,833 (22.4%)	0.076	0.000
January 2022	7,265 (12.1%)	6,733 (12.7%)	0.019	0.000
February 2022	2,778 (4.6%)	2,141 (4.0%)	0.028	0.000
March 2022	1,697 (2.8%)	1,346 (2.5%)	0.017	0.000
April 2022	1,925 (3.2%)	1,806 (3.4%)	0.012	0.000
May 2022	1,516 (2.5%)	1,380 (2.6%)	0.005	0.000
June 2022	1,076 (1.8%)	841 (1.6%)	0.016	0.000
July 2022	1,067 (1.8%)	786 (1.5%)	0.023	0.000
August 2022	480 (0.8%)	327 (0.6%)	0.022	0.000

Supplemental Table 4. Sensitivity analyses results using different endpoint definitions and using both IPTW and PS-matching

		RD (95% CI)			RR (95% CI)		
Endpoint	Time point	Unadjusted	IPTW	PS matching	Unadjusted	IPTW	PS matching
COVID-19 hospitalization	90 days	-0.97 (-1.63, -0.35)	-1.12 (-1.73, -0.51)	-1.20 (-1.88, -0.53)	0.70 (0.54, 0.87)	0.66 (0.52, 0.83)	0.65 (0.51, 0.83)
	180 days	-1.70 (-2.76, -0.72)	-1.69 (-2.63, -0.71)	-1.77 (-2.76, -0.73)	0.74 (0.61, 0.88)	0.74 (0.62, 0.88)	0.74 (0.62, 0.88)
	270 days	-2.34 (-3.73, -0.94)	-2.44 (-3.78, -1.09)	-2.49 (-4.02, -1.01)	0.76 (0.65, 0.90)	0.76 (0.65, 0.89)	0.75 (0.64, 0.89)
COVID-19 hospitalization with more restricted respiratory distress	90 days	-1.20 (-1.93, -0.49)	-1.20 (-1.69, -0.69)	-1.20 (-1.93, -0.49)	0.65 (0.50, 0.84)	0.65 (0.54, 0.78)	0.65 (0.50, 0.84)
	180 days	-1.77 (-2.79, -0.79)	-1.77 (-2.51, -1.03)	-1.77 (-2.79, -0.79)	0.74 (0.62, 0.87)	0.74 (0.65, 0.84)	0.74 (0.62, 0.87)
	270 days	-2.49 (-3.94, -1.03)	-2.49 (-3.66, -1.35)	-2.49 (-3.94, -1.03)	0.75 (0.64, 0.89)	0.75 (0.66, 0.86)	0.75 (0.64, 0.89)
COVID-19 hospitalization with respiratory distress using both open and closed claims	90 days	-0.76 (-1.30, -0.23)	-0.89 (-1.46, -0.29)	-0.94 (-1.61, -0.29)	0.71 (0.55, 0.90)	0.66 (0.50, 0.87)	0.65 (0.49, 0.88)
	180 days	-1.55 (-2.38, -0.75)	-1.58 (-2.48, -0.77)	-1.76 (-2.81, -0.80)	0.71 (0.58, 0.85)	0.70 (0.57, 0.84)	0.68 (0.54, 0.84)
	270 days	-1.76 (-2.92, -0.60)	-1.95 (-3.24, -0.73)	-2.04 (-3.33, -0.70)	0.76 (0.64, 0.91)	0.75 (0.61, 0.90)	0.74 (0.61, 0.90)
Medically attended COVID-19 using both open and closed claim	90 days	-3.65 (-5.93, -1.50)	-3.15 (-5.57, -0.79)	-2.71 (-5.11, -0.31)	0.91 (0.85, 0.96)	0.92 (0.86, 0.98)	0.93 (0.87, 0.99)
	180 days	-7.03 (-10.42, -3.67)	-4.96 (-8.58, -1.35)	-5.35 (-8.84, -1.89)	0.91 (0.87, 0.95)	0.94 (0.89, 0.98)	0.93 (0.89, 0.98)

	270 days	-5.82 (-10.92, -0.52)	-2.78 (-7.93, 2.87)	-3.70 (-9.46, 1.78)	0.96 (0.92, 1.00)	0.98 (0.94, 1.02)	0.97 (0.93, 1.01)
--	----------	-----------------------	---------------------	---------------------	-------------------	-------------------	-------------------

CI, confidence interval; IPTW, inverse probability of treatment weighting; RD, Risk difference in 1,000 persons; RR, Risk ratio; PS, propensity score.

Supplemental Table 5. Baseline characteristics of mRNA-1273 and BNT1262b groups after PS matching

	BNT162b	mRNA 1273	ASD after matching
Number of patients	48747	48747	
Month/Year of Cohort Entry Date			
February 2021; n (%)	0 (0.0%)	0 (0.0%)	0
March 2021; n (%)	13 (0.0%)	14 (0.0%)	0.001
April 2021; n (%)	55 (0.1%)	53 (0.1%)	0.001
May 2021; n (%)	56 (0.1%)	55 (0.1%)	0.001
June 2021; n (%)	53 (0.1%)	52 (0.1%)	0.001
July 2021; n (%)	59 (0.1%)	52 (0.1%)	0.004
August 2021; n (%)	4,704 (9.6%)	4,692 (9.6%)	0.001
September 2021; n (%)	3,475 (7.1%)	3,447 (7.1%)	0.002
October 2021; n (%)	4,925 (10.1%)	4,848 (9.9%)	0.005
November 2021; n (%)	9,941 (20.4%)	9,927 (20.4%)	0.001
December 2021; n (%)	10,875 (22.3%)	10,905 (22.4%)	0.001
January 2022; n (%)	6,393 (13.1%)	6,411 (13.2%)	0.001
February 2022; n (%)	2,049 (4.2%)	2,102 (4.3%)	0.005
March 2022; n (%)	1,305 (2.7%)	1,320 (2.7%)	0.002
April 2022; n (%)	1,676 (3.4%)	1,671 (3.4%)	0.001
May 2022; n (%)	1,307 (2.7%)	1,272 (2.6%)	0.004
June 2022; n (%)	804 (1.6%)	832 (1.7%)	0.004
July 2022; n (%)	756 (1.6%)	773 (1.6%)	0.003
August 2022; n (%)	301 (0.6%)	321 (0.7%)	0.005
Age			
mean (sd)	52.94 (13.11)	52.89 (13.04)	0.004
median [IQR]	56.00 [45.00, 62.00]	55.00 [45.00, 62.00]	
Age categorization (18-29, 30-39, 40-49, 50-64, 65-74, 75+)			
18 - <30; n (%)	3,031 (6.2%)	2,965 (6.1%)	0.006
30 - <40; n (%)	4,986 (10.2%)	5,288 (10.8%)	0.02
40 - <50; n (%)	8,058 (16.5%)	8,114 (16.6%)	0.003
50 - <65; n (%)	26,756 (54.9%)	26,241 (53.8%)	0.021

65 - <75; n (%)	4,473 (9.2%)	4,772 (9.8%)	0.021
>= 75; n (%)	1,443 (3.0%)	1,367 (2.8%)	0.009
Female/male recat			
Female; n (%)	26,286 (53.9%)	26,267 (53.9%)	0.001
Male; n (%)	22,461 (46.1%)	22,480 (46.1%)	0.001
Primary Payer Type			
Commercial; n (%)	31,576 (64.8%)	31,482 (64.6%)	0.004
Medicare Advantage; n (%)	2,184 (4.5%)	2,148 (4.4%)	0.004
Medicaid; n (%)	14,189 (29.1%)	14,297 (29.3%)	0.005
missing; n (%)	798 (1.6%)	820 (1.7%)	0.004
Region (State re-categorization)			
Northeast; n (%)	8,537 (17.5%)	8,575 (17.6%)	0.002
Midwest; n (%)	16,960 (34.8%)	16,980 (34.8%)	0.001
South; n (%)	13,226 (27.1%)	13,170 (27.0%)	0.003
West; n (%)	10,024 (20.6%)	10,022 (20.6%)	0
Count of hospitalization events, 365 days			
mean (sd)	1.64 (7.38)	1.62 (7.54)	0.003
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	
Count of outpatient events, 365 days			
mean (sd)	38.41 (54.48)	38.34 (55.32)	0.001
median [IQR]	23.00 [13.00, 41.00]	22.00 [13.00, 40.00]	
Charlson comorbidity score categories, 365 days			
0; n (%)	13,323 (27.3%)	13,425 (27.5%)	0.005
1; n (%)	9,811 (20.1%)	9,734 (20.0%)	0.004
2+; n (%)	25,613 (52.5%)	25,588 (52.5%)	0.001
Frailty score categories, 365 days			
robust (0-0.149); n (%)	33,175 (68.1%)	33,212 (68.1%)	0.002
prefrail (0.15-0.249); n (%)	13,856 (28.4%)	13,839 (28.4%)	0.001
mild frailty (0.25-0.349); n (%)	1,514 (3.1%)	1,488 (3.1%)	0.003
moderate to severe frailty (>=0.35) ; n (%)	202 (0.4%)	208 (0.4%)	0.002
Baseline comorbidities; n (%)			
Alcohol use; n (%)	2,700 (5.5%)	2,721 (5.6%)	0.002
Arrhythmia; n (%)	12,110 (24.8%)	12,165 (25.0%)	0.003

Asthma; n (%)	7,982 (16.4%)	7,997 (16.4%)	0.001
Cancer; n (%)	10,348 (21.2%)	10,352 (21.2%)	0
Cardiovascular disease; n (%)	31,526 (64.7%)	31,497 (64.6%)	0.001
Cerebrovascular disease; n (%)	3,824 (7.8%)	3,842 (7.9%)	0.001
Coronary artery disease; n (%)	5,866 (12.0%)	5,909 (12.1%)	0.003
Chronic kidney disease; n (%)	8,235 (16.9%)	8,149 (16.7%)	0.005
Chronic lung disease; n (%)	11,992 (24.6%)	12,038 (24.7%)	0.002
COPD; n (%)	5,819 (11.9%)	5,866 (12.0%)	0.003
Dementia; n (%)	509 (1.0%)	522 (1.1%)	0.003
Diabetes; n (%)	11,141 (22.9%)	11,090 (22.8%)	0.002
Down's syndrome; n (%)	50 (0.1%)	47 (0.1%)	0.002
Congestive heart failure; n (%)	3,672 (7.5%)	3,638 (7.5%)	0.003
Hypertension; n (%)	25,888 (53.1%)	25,813 (53.0%)	0.003
Liver disease; n (%)	7,009 (14.4%)	7,039 (14.4%)	0.002
Obesity; n (%)	15,873 (32.6%)	15,853 (32.5%)	0.001
Influenza or RSV; n (%)	543 (1.1%)	535 (1.1%)	0.002
Psoriasis; n (%)	3,663 (7.5%)	3,616 (7.4%)	0.004
Psoriatic arthritis; n (%)	3,294 (6.8%)	3,254 (6.7%)	0.003
Rheumatoid arthritis; n (%)	6,736 (13.8%)	6,702 (13.7%)	0.002
Sickle cell disease or thalassemia; n (%)	119 (0.2%)	125 (0.3%)	0.002
History of tobacco use/smoking; n (%)	13,711 (28.1%)	13,719 (28.1%)	0
Irritable Bowel Syndrome; n (%)	22,540 (46.2%)	22,575 (46.3%)	0.001
Number of unique immunosuppressive medication			
mean (sd)	0.94 (1.00)	0.94 (1.00)	0
median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	
COVID-19 infection [-180,-1]; n (%)	2,774 (5.7%)	2,799 (5.7%)	0.002

ASD, absolute standardized differences; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; RD, Risk difference in 1,000 persons; RR, Risk ratio; RSV, respiratory syncytial virus; PS, propensity score; SD, standard deviation.

Supplemental Table 6. Sensitivity analysis results using PS matching

Endpoint	Time points	PS matched	
		RD (95% CI)	RR (95% CI)
COVID-19 hospitalization with respiratory distress	90 days	-0.876 (-1.325, -0.409)	0.667 (0.537, 0.824)
	180 days	-1.683 (-2.366, -1.038)	0.682 (0.577, 0.785)
	270 days	-1.769 (-2.797, -0.822)	0.761 (0.647, 0.880)
Medically attended COVID-19 infection	90 days	-2.702 (-4.993, -0.317)	0.927 (0.870, 0.991)
	180 days	-5.429 (-8.943, -1.958)	0.931 (0.889, 0.975)
	270 days	-4.179 (-9.403, 1.489)	0.967 (0.927, 1.012)

CI, confidence interval; RD, Risk difference in 1,000 persons; RR, Risk ratio; PS, propensity score.

Supplemental Table 7. Crude rates of two study endpoints among subgroups


Subgroups	Endpoints	BNT162b	mRNA-1273
Age 65+	COVID-19 hospitalization with respiratory distress	18.925 (14.613, 23.237)	13.664 (9.914, 17.415)
	Medically attended COVID-19 infection	160.625 (147.783, 173.467)	142.993 (130.631, 155.355)
Without COVID-19 infection within 6 month prior to the index day	COVID-19 hospitalization with respiratory distress	9.691 (8.619, 10.763)	7.646 (6.621, 8.670)
	Medically attended COVID-19 infection	172.183 (167.542, 176.823)	160.148 (155.347, 164.950)
Primary Immunodeficiency	COVID-19 hospitalization with respiratory distress	8.177 (6.174, 10.181)	6.501 (4.622, 8.379)
	Medically attended COVID-19 infection	141.818 (133.297, 150.340)	139.523 (130.636, 148.409)
Active cancer	COVID-19 hospitalization with respiratory distress	8.930 (6.013, 11.847)	4.880 (2.560, 7.200)
	Medically attended COVID-19 infection	159.462 (146.838, 172.085)	140.282 (127.586, 152.978)
Patients with HIV	COVID-19 hospitalization with respiratory distress	6.255 (4.182, 8.327)	5.312 (3.308, 7.315)
	Medically attended COVID-19 infection	129.242 (119.633, 138.851)	135.177 (124.864, 145.490)

Supplemental Table 8. The censoring reason distribution in main analysis

	BNT162b n (%)	mRNA 1273 n (%)	Overall n (%)
COVID-19 hospitalization with respiratory distress			
Outcome	342 (0.6)	232 (0.4)	574 (0.5)
Specified date reached	36,970 (61.5)	31,625 (59.7)	68,595 (60.7)
End of patient enrollment	10,928 (18.2)	9,191 (17.4)	20,119 (17.8)
Receiving any COVID-19 vaccine after start of follow-up	11,844 (19.7)	11,895 (22.5)	23,739 (21.0)
Medically attended COVID-19 infection			
Outcome	5,784 (9.6)	4,656 (8.8)	10,440 (9.2)
Specified date reached	33,189 (55.2)	28,448 (53.7)	61,637 (54.5)
End of patient enrollment	10,021 (16.7)	8,608 (16.3)	18,629 (16.5)
Receiving any COVID-19 vaccine after start of follow-up	11,090 (18.5)	11,231 (21.2)	22,321 (19.7)

Supplemental Figure 1. Kaplan–Meier plots of mRNA-1273 versus BNT162b on A) COVID-19 hospitalization; B) Medically attended COVID-19, throughout the full follow-up.

A



B

